Discussion and generalized conclusions, therefore, a clinical result similar to the traditional regimen of treatment with ursosan VPH in chronic hepatitis and cirrhosis of the liver can be achieved with the use of lower dosages of the drug. The use of an individualized (alternative) scheme for the use of ursosan for the treatment of CPH based on the results of biochemical studies (bilirubin and GGTP) every 30 days will save money on the purchase of the drug for the course treatment of each patient with chronic hepatitis in the range of 643,500 soums, 430,500 soums and 325,500 soums, respectively, for mild, moderate and severe CPH. And also in the amount of 174,000 soums, 525,000 soums and 400,500 soums for the treatment of each patient with cirrhosis of the liver, respectively, with mild, moderate and severe CPH.

cholestatic syndrome, ursotherapy, chronic liver diseases (CKD), intrahepatic cholestasis syndrome (ITH), remainsursodeoxycholic acid (UDCA), gastrointestinal tract (GIT).